OR WAIT null SECS
We are now less than three weeks away from the initial sign up period for Obamacare. After October 1st, the reality of the program and all that it portends for the future of the US pharmaceutical industry will begin to make itself apparent
We are now less than three weeks away from the initial sign up period for Obamacare. After October 1st, the reality of the program and all that it portends for the future of the US pharmaceutical industry will begin to make itself apparent. One area that is of extreme concern to Rx brand managers across the country is, “Will my drug be covered under Obamacare?” The apparent answer to that important question is - it depends.
Why the vague response? To begin, let’s review the latest February 2013 HHS regulatory statements on access to prescription medicines under Obamacare laid out in the so called 10 “Essential Health Benefits” (EHB). This outline will drive all medical service under the new Obamacare program. In its final rule on the drugs to be covered under the program it notes, “Each participating state must offer at least - the greater of one drug for each USP category and class - or the number of drugs in the state EHB “benchmark” plan.”
What does this mean? Well, following public outcries from patients after the initial December 16, 2011 EHB drug rule was issued, which suggested that only one drug per therapeutic class would be needed to satisfy the requirements of the Obamacare formulary, HHS backtracked. This winter the agency concluded that the current formulary of each state’s “benchmark” health insurance plan could be used to determine if additional drugs might be available to Obamacare patients. However, the rule also seems to suggest that the states do not necessarily have to include these additional drugs. So maybe one drug per therapeutic class will be available? Maybe more? Is it up to the states to decide?
It’s not clear at the moment.
So let’s piece together what we do know at this point and attempt to answer what we can about Obamacare drug coverage - three weeks before this program is supposed to begin signing up patients.
A recent 2012 Avalere Health study, underwritten by Pfizer, totaled up the number of drugs currently available under each state’s likely exchange “benchmark” healthcare plan. The study concluded the following:
But the question remains: Will the states adopt the EHB “one drug per therapeutic class” approach, or the state’s “benchmark” approach? Currently, 25 states including California and New York have submitted their “benchmark” plans to HHS. The rest have not, so the exact disposition of the state exchanges in many states is not known today. (For the latest up-to-date info on all state exchanges, bookmark this page.)
Certainly the most interesting study I have found on the question of Obamacare drug pricing was published on July 11th, 2013 by insurance reviewer HealthPocket.com. While the study does not actually answer what drugs will be covered, it does give us some very clear clues about what drugs may be selected for reimbursement, and those that will not.
Here are some highlights from the review:
The results of their survey are fascinating and may assist you in your search for answers on reimbursement of your product under Obamacare. Here are their findings:
First, HealthPocket.com examined publicly available rate filings for 2014 Obamacare Bronze Plans, Silver Plans, Gold Plans, and Platinum Plans to determine what copay consumers will pay for drugs.
Based on this review HealthPocket.com reported that, overall, as a consumer climbs up the Obamacare “metal” ladder (i.e., Bronze to Silver, etc.), the premium paid for health plan coverage is higher - but the corresponding drug formulary expands, and copays for drugs go down. This, of course, is not unusual in today’s insurance market. However, what is unusual is comparing the copays that current individual and family health plans are charging for service today versus what the EHB state “benchmark”s apparently will charge in 2014.
The report found that average out-of-pocket copayments, particularly for the “Bronze” & “Silver” healthcare drug programs, (those plans likely to be utilized by those with the lowest incomes, or young people who just want basic coverage) will go up, substantially. Consider these findings:
The average copay for a “generic” formulary product in today’s current health plan environment is $11.72. HealthPocket.com reports that the average copay for “generics” reviewed under Obamacare state exchanges will come in at $20.24 for “Bronze Plan” patients, an increase of 73% versus today’s copays; while the “Silver Plan” that requires higher premiums will drive the average copays down to $13.44. But this is still an increase of 15% over current copay charges for generics.
On the other hand, the average copay for a “preferred brand” product on formulary in the current health plan environment is $36.37. However, like the generics, HealthPocket.com reports that average copays for “preferred brands” reviewed under Obamacare state exchanges will come in higher at $58.47 for “Bronze Plan” patients, or a 61% increase versus today’s copays. Meanwhile, the higher “Silver Plan” premiums will drive the average drug copays down to $41.33, still an increase of 14% when compared to current plan copays for “preferred brand” products.
HealthPocket.com’s finding: “When compared to the current individual and family health insurance market, both the entry-level “Bronze” and the higher tier “Silver” “benchmark” plans will increase most out-of-pocket drug costs for consumers.”
So what does this tell us?
First, people who currently have drug insurance, and may choose to join, or be forced into Obamacare state exchange offerings, are going to pay more out of pocket for the same category of products, at least for generics and “preferred brands,” than they are today under their current plans.
Secondly, even with elevated copays, the absolute copay cost differentials between generics and “preferred brands” will continue to be as substantial as they are today. This suggests that when a consumer enrolled in either a “Bronze” or “Silver” plan must make a decision between a prescribed “preferred brand” product or a “generic” in the same therapeutic class, the person will likely opt for the lower priced generic product. So, even though you don’t currently know specifically that your product is on an Obamacare state exchange formulary, this economic reality is definitely not good news for brand name product managers.
Thirdly, HealthPocket.com’s study is silent on the fate of “non-preferred brand products”, that is, all the other drugs in a therapeutic class that are not “preferred.” This is because data on the “non-preferred brand products” was not available to the authors. Can we infer, perhaps, that this was so because few, if any “non-preferred brand products” were available to be evaluated on the current state “benchmark” formularies? Frankly, it would be hard to believe, especially when you look over the Rx summaries from the Avalere study.
However, per the February 2013 HHS rule, is it possible that states could decide to rework their current formularies, offering, say, one generic and one “preferred brand” per therapeutic class - and that would be it? Not realistic you say? Think about how many states are currently running huge deficits and what this new healthcare obligation is going to do to their future debt. Given my 25 years of experience with state Medicaid formularies, I would suggest an Rx solution like this is very realistic.
So, extrapolating these facts to the expected 30 million Americans who are expected to sign up for Obamacare after October 1st, and anticipating that large numbers of these individuals will opt for the lowest cost “Bronze” programs because of low income subsidies, or their relatively young ages, it’s fairly apparent the brand name industry faces real challenges in getting their products covered for this large new patient population.
A few obvious take-aways for drug product managers include:
So will your prescription product be covered under Obamacare’s Rx scheme? As stated at the beginning of this review, it depends. My guess is that unless you have managed to negotiate a “preferred brand” status for your product with each of the state “benchmark” formularies, or found a way to have them accept a “branded generic” deal (think Lipitor) – your product will likely be relegated to the third-tier of their formularies. And long term, this is certainly not a good position to be in if your goal is to expand your product’s market share within the massive, new Obamacare patient population.
Tom Norton is principal at NHD Smart Communications. He can be reached at email@example.com